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Introduction 
Quantitative and functional alterations of professional antigen-presenting cells (APC) in SIL suggest that these lesions may have a diminished capacity to
 capture viral antigens. Moreover, GM-CSF (whose production is decreased in HPV-transformed keratinocytes) is an essential factor for the migration of APC in
 cervical (pre)neoplastic lesions formed in vitro and transplanted in vivo on mouse. In this study we performed a phase I/II clinical trial in order to determine
 whether a local application of GM-CSF on cervical low-grade squamous intraepithelial lesions (LSIL) might increase the recruitment of APC into the epithelium
 and indirectly the viral antigen presentation to the immune system.
Clinical protocol: 15 patients with LSIL (10 GM-CSF and 5 placebo) were enrolled in this study
 (table 1). At visit A (week -35 to -5) and B (week -21 to -1) a colposcopy and sampling for viral
 detection and DNA load determination were performed. The confirmation of LSIL was performed on
 biopsies obtained either at visit A or B. GM-CSF (4 applications, 800.000 IU/ml) or placebo gel was
 applied at visit C (Week 0). Follow up was performed at visit D (week 2), visit E (week 6 to 15) and F
 (week 23 to 42). 
APC and CTL infiltration was quantified by immunostaining with anti-CD1a and CD8 mAb
 respectively. Cellular immune response was evaluated by using an IFN-γ   intracellular staining on
 PBMC stimulated in vitro with the E7 HPV16 protein and L1 HPV16 Virus-like particles (VLP).  
The HPV genotyping was determined on cervical brush specimens using PapilloCheck Test Kit
 (Greiner Bio One). Hybrid capture Digene was performed to semi-quantify the viral DNA in
 cervical brush specimens. Since the test was conducted in a double-blind way, we observed at the
 end of test that placebo patients (29 ± 6 years) was significantly younger than the patients receiving
 the GM-CSF (37 ± 6 years, p< 0.05) (Table 1).
GM-CSF applications were well tolerated in all patients. No difference in the cytological
/histological and viral parameters assessed at 2 and 6 months (Fig. 1) after the last
 application was observed between the GM-CSF and the placebo group. An increased
 number of CD1a+ APC was observed in 8/10 patients treated by GM-CSF compared
 to 1/5 patient in the placebo group (Fig. 2 A-C). We also observed a higher infiltration
 of CTL (CD8+) in GM-CSF treated-patients (Fig. 2 D). In the patient cohort, before the
 treatment only 3 patients were HPV16+ in the GM-CSF-treated group and none in the
 placebo group. All these 3 patients exhibited an immune response against HPV16 after
 GM-CSF application as showed by NK and/or T cells producing IFN-γ after stimulation
 with E7 HPV16 or VLP HPV16. (Fig. 3). We also tested the anti-HPV16 response in
 PBMC from patients negative for HPV16; a trend of a higher percentage of
 lymphocytes expressing IFNγ after stimulation with HPV16 L1-VLP was observed in
 GM-CSF group compared to placebo patients (Fig. 4).  
Materials and methods	
Results 
N° Age Cervix HPV type Viral load before 
treatment  
G1 41 LSIL 59/70 21 
G2 34 LSIL 35 955 
G3 33 LSIL 18 11 
G4 45 LSIL 16/31/53 1183 
G5 41 LSIL 16/56/66 74 
G6 36 LSIL 56/59/66 37 
G7 29 LSIL 43/44-55 /52  30 
G8 47 LSIL 42/44-55/52/53 /70  133 
G9 35 LSIL 53/56 4 
G10 31 LSIL 16/52  410 
P1 27 LSIL 31/44-55 /53  37 
P2 30 LSIL 3 9  0 
P3 37 LSIL 6 8  7 
P4 21 LSIL 56/66  40 
P5 29 LSIL 66 6 
 
A. Before treatment 

























































































































Table 1: List of women enrolled in clinical trials  
G1-G10 patients receiving GM-CSF; P1-P5 placebo patient 
Figure 1: Clinical response  
The evaluation of the lesion grade was assessed by cytological examination of
 Papanicolaou stained cervical smears and histologicaly on cervical biopsies. Viral








































Figure 2. Infiltration of APC (CD1a+) and CTL (CD8+) in cervical LSIL.  
Representative pictures of immunostaining of CD1a+ cells before (A) and after GM-CSF treatment (B). Number of
 patients with increased infiltration of CD1a+ cells at week 2 and/or week 23-42 after application of GM-CSF or
 placebo gel (C). Number of patients with increased infiltration of CD8+ cells in the epithelium or in the stroma at












































These encouraging results obtained
 from a limited number of subjects
 justify further analysis of the
 therapeutic effect of GM-CSF in
 cervical preneoplastic lesions.  
Figure 3. IFNγ production in response to HPV16 E7 or HPV16 L1-VLP in
 HPV16 positive patients.  
PBMC were stimulated overnight with HPV16 E7 or L1-VLP and the
 percentage of IFNγ+ cells was determined in CD4+, CD8+ or
 CD56+CD16+CD3- (NK cells) gated cell populations. 
Figure 4. IFNγ production in response to HPV16 L1-VLP in
 HPV16 negative patients.  
PBMC were stimulated overnight with HPV16 VLP L1 and the
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